[Curative radiotherapy of oligometastatic cancer: long-term results of the SABR-COMET phase II trial].
作者信息
Dunst Jürgen
机构信息
Klinik für Strahlentherapie, Campus Kiel, Universitätsklinikum Schleswig-Holstein, Feldstr. 21, 24105, Kiel, Deutschland.
出版信息
Strahlenther Onkol. 2021 Apr;197(4):365-367. doi: 10.1007/s00066-021-01745-w. Epub 2021 Feb 2.
Abstract
摘要
相似文献
1
[Curative radiotherapy of oligometastatic cancer: long-term results of the SABR-COMET phase II trial].[寡转移癌的根治性放疗：SABR-COMET II期试验的长期结果]
Strahlenther Onkol. 2021 Apr;197(4):365-367. doi: 10.1007/s00066-021-01745-w. Epub 2021 Feb 2.
2
Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.立体定向消融放疗治疗 4-10 个寡转移肿瘤的综合治疗（SABR-COMET-10）：一项随机 III 期试验的研究方案。
BMC Cancer. 2019 Aug 19;19(1):816. doi: 10.1186/s12885-019-5977-6.
3
Stereotactic radiotherapy in oligometastatic cancer.寡转移癌的立体定向放射治疗。
Chin Clin Oncol. 2017 Sep;6(Suppl 2):S16. doi: 10.21037/cco.2017.06.20.
4
A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE).一项关于寡转移前列腺癌观察与立体定向消融放疗对比的II期随机试验（ORIOLE）。
BMC Cancer. 2017 Jun 29;17(1):453. doi: 10.1186/s12885-017-3455-6.
5
Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial.立体定向消融放疗治疗 1-3 处寡转移瘤的综合治疗（SABR-COMET-3）：一项随机 III 期试验的研究方案。
BMC Cancer. 2020 May 5;20(1):380. doi: 10.1186/s12885-020-06876-4.
6
A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic disease in the context of new consensus definitions.新共识定义下立体定向消融放疗治疗寡转移疾病的临床试验综述。
Ann Palliat Med. 2021 May;10(5):6045-6051. doi: 10.21037/apm-20-847. Epub 2020 Aug 7.
7
[Radiotherapy].[放射治疗]
Gan To Kagaku Ryoho. 2023 Aug;50(8):845-848.
8
Oligometastatic breast cancer: where are we now and where are we headed?-a narrative review.寡转移乳腺癌：我们现在在哪里，未来在哪里？——一篇叙述性综述。
Ann Palliat Med. 2021 May;10(5):5954-5968. doi: 10.21037/apm-20-1128. Epub 2020 Sep 10.
9
Prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET/CT)-guided stereotactic ablative body radiotherapy for oligometastatic prostate cancer: a single-institution experience and review of the published literature.前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描（PSMA-PET/CT）引导下的立体定向消融体部放射治疗寡转移前列腺癌：单机构经验及已发表文献综述
BJU Int. 2019 Nov;124 Suppl 1:19-30. doi: 10.1111/bju.14886. Epub 2019 Sep 11.
10
Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer.立体定向消融放疗（SAbR）用于延缓寡转移肾细胞癌的全身治疗。
Int J Radiat Oncol Biol Phys. 2019 Oct 1;105(2):367-375. doi: 10.1016/j.ijrobp.2019.07.023. Epub 2019 Aug 1.
引用本文的文献
1
Stereotactic body radiotherapy as metastasis-directed therapy in oligometastatic prostate cancer: a systematic review and meta-analysis of randomized controlled trials.立体定向体部放疗作为寡转移前列腺癌的转移灶定向治疗：一项随机对照试验的系统评价和荟萃分析
Radiat Oncol. 2024 Dec 17;19(1):173. doi: 10.1186/s13014-024-02559-7.
2
Discussion of ABC7 Consensus and German Recommendations.ABC7共识与德国建议的讨论。
Geburtshilfe Frauenheilkd. 2024 May 29;84(5):431-442. doi: 10.1055/a-2263-5152. eCollection 2024 May.
3
ABC7 Consensus: Assessment by a German Group of Experts.ABC7共识：德国专家小组的评估
Breast Care (Basel). 2024 Apr;19(2):116-128. doi: 10.1159/000535997. Epub 2024 Jan 24.
Zotero 插件